Belnacasan - Vertex Pharmaceuticals
Alternative Names: UNII-00OLE78529; VX-765Latest Information Update: 05 Jan 2022
At a glance
- Originator Vertex Pharmaceuticals
- Developer MedStar Health Research Institute; Vertex Pharmaceuticals
- Class Aminobenzoic acids; Antipsoriatics; Dipeptides; Small molecules
- Mechanism of Action Caspase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Discontinued Cardiovascular disorders; Cryopyrin-associated periodic syndromes; Epilepsy; Inflammation; Psoriasis
Most Recent Events
- 14 Dec 2021 Phase-II clinical trials in COVID-2019 infections in USA (PO) (NCT05164120)
- 30 Sep 2012 Discontinued - Phase-II for Cryopyrin-associated periodic syndromes (In adolescents, In the elderly, In adults) in United Kingdom (PO)
- 31 Dec 2011 Vertex Pharmaceuticals initiates enrolment in a Phase-IIb trial for treatment-resistant epilepsy in USA (NCT01501383)